Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of subcutaneous efgartigimod PH20 in adults with primary immune thrombocytopenia
MOH_2021-03-14_009829Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Mar 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing efgartigimod PH20 SC with matching placebo PH20 SC (2 arms). Planned start Mar 2021; status: not yet recruiting.
02
Drugs
efgartigimod alfaENHANZE
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on MOH_2021-03-14_009829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-14_009829.